Trial Profile
AG-013736 (AXITINIB) FOR THE TREATMENT OF METASTATIC RENAL CELL CANCER
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Sorafenib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms AGILE
- Sponsors Pfizer
- 18 May 2021 Status changed from active, no longer recruiting to completed.
- 06 Apr 2021 Planned End Date changed from 6 Jan 2021 to 30 Apr 2021.
- 28 Oct 2020 Planned End Date changed from 30 Sep 2020 to 6 Jan 2021.